Efficacy and Safety of Fluvoxamine as Outpatient Treatment for Patients With Covid-19: A Systematic Review and Meta-analysis of Clinical Trials.

ABSTRACT:

Background

Fluvoxamine may be beneficial for the management of coronavirus disease 2019 (Covid-19) because of its effect on the sigma-1 receptor. Available evidence from randomized clinical trials (RCTs) has shown conflicting results.

Objective

This study sought to analyze the efficacy and safety of fluvoxamine as an outpatient treatment for Covid-19.

Methods

Using specific keywords, we comprehensively go through the potential articles on PubMed, Scopus, Europe PMC, and ClinicalTrials.gov sources until February 1, 2023. We collected all published clinical trials on fluvoxamine and Covid-19. We were using Review Manager 5.4 to conduct statistical analysis.

Results

We include a total of 6 trials. Our pooled analysis revealed that fluvoxamine did not offer any sig

SUBMITTER: Vatvani AD 

PROVIDER: S-EPMC10067701 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature